AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMUGENE LTD

0.054

-0.004-6.90%

Volume:3.21M

Turnover:176.76K

Market Cap:29.64M

PE:-0.17

High:0.059

Open:0.059

Low:0.054

Close:0.058

52wk High:0.460

52wk Low:0.054

Shares:548.90M

Float Shares:254.20M

Volume Ratio:1.39

T/O Rate:1.26%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.323

EPS(LYR):-0.323

ROE:-313.99%

ROA:-123.50%

PB:3.29

PE(LYR):-0.17

Loading ...

Overview Company News Filings

Company Profile

Company Name:

IMUGENE LTD

Exchange:

ASX

Establishment Date:

- -

Employees:

14

Office Location:

4-6 Bligh Street,Suite 12.01, Level 12,Sydney,New South Wales,Australia

Website:

http://www.imugene.com

Zip Code:

2000

Phone:

Fax:

61 2 9423 0881

Introduction:

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/IMU.AU/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IMU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","market":"AU","secType":"STK","nameCN":"IMUGENE LTD","latestPrice":0.054,"timestamp":1789107120000,"preClose":0.058,"halted":0,"volume":3206030,"delay":0,"changeRate":-0.06896551724137936,"nameEN":"IMUGENE LTD","floatShares":254199099,"shares":548901511,"eps":-0.323022,"marketStatus":"Not Yet Opened","change":-0.004,"latestTime":"09-11 16:12:00 AEST","open":0.059,"high":0.059,"low":0.054,"amount":176757,"amplitude":0.086207,"askPrice":0.058,"askSize":87900,"bidPrice":0.054,"bidSize":211636,"shortable":3,"etf":0,"ttmEps":-0.323022,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789344000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.058,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":1.3900883552491505,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMU.AU","preClose":0.058,"auctionPrice":0.054,"auctionVolume":134647,"auction":3,"marketStatus":"盘后竞价","timestamp":1789106947263}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","floatShares":254199099,"roa":"-123.50%","roe":"-313.99%","lyrEps":-0.323022,"volumeRatio":1.3900883552491505,"shares":548901511,"dividePrice":0,"high":0.059,"amplitude":0.086207,"preClose":0.058,"low":0.054,"week52Low":0.054,"pbRate":"3.29","psRate":"14.21","week52High":0.46,"institutionHeld":0,"latestPrice":0.054,"committee":0.413092,"eps":-0.323022,"divideRate":0,"volume":3206030,"delay":0,"ttmEps":-0.323022,"open":0.059,"prevYearClose":0.365,"prevWeekClose":0.069,"prevMonthClose":0.068,"prevQuarterClose":0.115,"fiveDayClose":0.069,"twentyDayClose":0.082,"sixtyDayClose":0.115},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMU.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-07-02","symbol":"IMU.AU","type":"split","dateTimestamp":1751378400000,"forFactor":34,"toFactor":1,"ratio":34}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":[],"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":11113368,"employeeNum":14,"address":"4-6 Bligh Street,Suite 12.01, Level 12,Sydney,New South Wales,Australia","zipCode":"2000","officePhone":"61 2 9423 0881","officeFax":"61 2 9423 0881","fiscalYearEnd":"06-30"},"stockCompanyDetail":{"websiteUrl":"http://www.imugene.com","stockEarnings":[{"period":"1week","weight":-0.2174},{"period":"1month","weight":-0.3415},{"period":"3month","weight":-0.4066},{"period":"6month","weight":-0.7081},{"period":"1year","weight":-0.8105},{"period":"ytd","weight":-0.8521}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":-0.026},{"period":"3month","weight":0.0239},{"period":"6month","weight":0.0491},{"period":"1year","weight":0.0897},{"period":"ytd","weight":0.0274}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.034991},{"month":2,"riseRate":0.291667,"avgChangeRate":-0.044685},{"month":3,"riseRate":0.416667,"avgChangeRate":0.028881},{"month":4,"riseRate":0.25,"avgChangeRate":-0.014779},{"month":5,"riseRate":0.125,"avgChangeRate":-0.102646},{"month":6,"riseRate":0.625,"avgChangeRate":0.170292},{"month":7,"riseRate":0.5,"avgChangeRate":0.036442},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.022663},{"month":9,"riseRate":0.458333,"avgChangeRate":0.044309},{"month":10,"riseRate":0.541667,"avgChangeRate":0.1478},{"month":11,"riseRate":0.291667,"avgChangeRate":0.035512},{"month":12,"riseRate":0.25,"avgChangeRate":-0.058143}],"exchange":"ASX","name":"IMUGENE LTD","nameEN":"IMUGENE LTD"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":null}}